Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886094 | 0.92 | OPRM1 (0.34) | KMT2AALDH1A1MEN1OPRM1GAA | |
| SCHEMBL4563480 | 0.90 | HPGD (0.34) | KMT2AHPGDMEN1OPRM1HSP90AA1 | |
| SCHEMBL4889118 | 0.88 | SIGMAR1 (0.36) | KMT2AALDH1A1GAAKDM4ELMNA | |
| SCHEMBL4880934 | 0.84 | UTS2R (0.38) | KMT2AALDH1A1MEN1 | |
| SCHEMBL4430432 | 0.84 | ALDH1A1 (0.35) | KMT2AHPGDALDH1A1MEN1GAA | |
| SCHEMBL4432781 | 0.83 | NPFFR1 (0.36) | KMT2AHPGDALDH1A1MEN1GAA | |
| SCHEMBL4886384 | 0.82 | POLB (0.41) | KMT2AHPGDALDH1A1MEN1KDM4E | |
| SCHEMBL15808512 | 0.82 | EPHX2 (0.37) | HPGDALDH1A1TSHR | |
| SCHEMBL4440078 | 0.81 | UTS2R (0.36) | — | |
| SCHEMBL4431342 | 0.81 | PRCP (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | KMT2A 3204/4885HPGD 1252/4885ALDH1A1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.